Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2

Yun Han Lee, Daekwan Seo, Kyung Ju Choi, Jesper B. Andersen, Min Ah Won, Mitsuteru Kitade, Luis E. Gómez-Quiroz, Adam D. Judge, Jens U. Marquardt, Chiara Raggi, Elizabeth A. Conner, Ian MacLachlan, Valentina M. Factor, Snorri S. Thorgeirsson

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting of this HDAC isoform is sufficient to inhibit HCC progression. siRNA-mediated silencing of HDAC inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. These effects were associated with deregulation of HDAC-regulated genes that control cell cycle, apoptosis, and lipid metabolism, specifically, by upregulation of p27 and acetylated p53 and by downregulation of CDK6 and BCL2. We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation. Notably, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles was sufficient to blunt the growth of human HCC in a murine xenograft model. Our findings offer preclinical proof-of-concept for HDAC2 blockade as a systemic therapy for liver cancer.

Original languageEnglish
Pages (from-to)4752-4761
Number of pages10
JournalCancer Research
Volume74
Issue number17
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Histone Deacetylase 2
Hepatocellular Carcinoma
Protein Isoforms
Apoptosis
Small Interfering RNA
Cell Cycle
cdc Genes
Lipogenesis
Peroxisome Proliferator-Activated Receptors
Glycolysis
Liver Neoplasms
Growth
Cell Cycle Checkpoints
Lipid Metabolism
Heterografts
Epigenomics
Nanoparticles
Chromatin
Cell Differentiation
Up-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Lee, Y. H., Seo, D., Choi, K. J., Andersen, J. B., Won, M. A., Kitade, M., ... Thorgeirsson, S. S. (2014). Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Research, 74(17), 4752-4761. https://doi.org/10.1158/0008-5472.CAN-13-3531

Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. / Lee, Yun Han; Seo, Daekwan; Choi, Kyung Ju; Andersen, Jesper B.; Won, Min Ah; Kitade, Mitsuteru; Gómez-Quiroz, Luis E.; Judge, Adam D.; Marquardt, Jens U.; Raggi, Chiara; Conner, Elizabeth A.; MacLachlan, Ian; Factor, Valentina M.; Thorgeirsson, Snorri S.

In: Cancer Research, Vol. 74, No. 17, 01.09.2014, p. 4752-4761.

Research output: Contribution to journalArticle

Lee, YH, Seo, D, Choi, KJ, Andersen, JB, Won, MA, Kitade, M, Gómez-Quiroz, LE, Judge, AD, Marquardt, JU, Raggi, C, Conner, EA, MacLachlan, I, Factor, VM & Thorgeirsson, SS 2014, 'Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2', Cancer Research, vol. 74, no. 17, pp. 4752-4761. https://doi.org/10.1158/0008-5472.CAN-13-3531
Lee YH, Seo D, Choi KJ, Andersen JB, Won MA, Kitade M et al. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Research. 2014 Sep 1;74(17):4752-4761. https://doi.org/10.1158/0008-5472.CAN-13-3531
Lee, Yun Han ; Seo, Daekwan ; Choi, Kyung Ju ; Andersen, Jesper B. ; Won, Min Ah ; Kitade, Mitsuteru ; Gómez-Quiroz, Luis E. ; Judge, Adam D. ; Marquardt, Jens U. ; Raggi, Chiara ; Conner, Elizabeth A. ; MacLachlan, Ian ; Factor, Valentina M. ; Thorgeirsson, Snorri S. / Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. In: Cancer Research. 2014 ; Vol. 74, No. 17. pp. 4752-4761.
@article{f0a55a5662e74e2ca042b437240a2ff4,
title = "Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2",
abstract = "Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting of this HDAC isoform is sufficient to inhibit HCC progression. siRNA-mediated silencing of HDAC inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. These effects were associated with deregulation of HDAC-regulated genes that control cell cycle, apoptosis, and lipid metabolism, specifically, by upregulation of p27 and acetylated p53 and by downregulation of CDK6 and BCL2. We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation. Notably, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles was sufficient to blunt the growth of human HCC in a murine xenograft model. Our findings offer preclinical proof-of-concept for HDAC2 blockade as a systemic therapy for liver cancer.",
author = "Lee, {Yun Han} and Daekwan Seo and Choi, {Kyung Ju} and Andersen, {Jesper B.} and Won, {Min Ah} and Mitsuteru Kitade and G{\'o}mez-Quiroz, {Luis E.} and Judge, {Adam D.} and Marquardt, {Jens U.} and Chiara Raggi and Conner, {Elizabeth A.} and Ian MacLachlan and Factor, {Valentina M.} and Thorgeirsson, {Snorri S.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-13-3531",
language = "English",
volume = "74",
pages = "4752--4761",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2

AU - Lee, Yun Han

AU - Seo, Daekwan

AU - Choi, Kyung Ju

AU - Andersen, Jesper B.

AU - Won, Min Ah

AU - Kitade, Mitsuteru

AU - Gómez-Quiroz, Luis E.

AU - Judge, Adam D.

AU - Marquardt, Jens U.

AU - Raggi, Chiara

AU - Conner, Elizabeth A.

AU - MacLachlan, Ian

AU - Factor, Valentina M.

AU - Thorgeirsson, Snorri S.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting of this HDAC isoform is sufficient to inhibit HCC progression. siRNA-mediated silencing of HDAC inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. These effects were associated with deregulation of HDAC-regulated genes that control cell cycle, apoptosis, and lipid metabolism, specifically, by upregulation of p27 and acetylated p53 and by downregulation of CDK6 and BCL2. We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation. Notably, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles was sufficient to blunt the growth of human HCC in a murine xenograft model. Our findings offer preclinical proof-of-concept for HDAC2 blockade as a systemic therapy for liver cancer.

AB - Histone deacetylase 2 (HDAC2) is a chromatin modifier involved in epigenetic regulation of cell cycle, apoptosis, and differentiation that is upregulated commonly in human hepatocellular carcinoma (HCC). In this study, we show that specific targeting of this HDAC isoform is sufficient to inhibit HCC progression. siRNA-mediated silencing of HDAC inhibited HCC cell growth by blocking cell-cycle progression and inducing apoptosis. These effects were associated with deregulation of HDAC-regulated genes that control cell cycle, apoptosis, and lipid metabolism, specifically, by upregulation of p27 and acetylated p53 and by downregulation of CDK6 and BCL2. We found that HDAC2 silencing in HCC cells also strongly inhibited PPARγ signaling and other regulators of glycolysis (ChREBPα and GLUT4) and lipogenesis (SREBP1C and FAS), eliciting a marked decrease in fat accumulation. Notably, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles was sufficient to blunt the growth of human HCC in a murine xenograft model. Our findings offer preclinical proof-of-concept for HDAC2 blockade as a systemic therapy for liver cancer.

UR - http://www.scopus.com/inward/record.url?scp=84907053778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907053778&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3531

DO - 10.1158/0008-5472.CAN-13-3531

M3 - Article

C2 - 24958469

AN - SCOPUS:84907053778

VL - 74

SP - 4752

EP - 4761

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 17

ER -